DSI) is a breathing system which includes a modification of an existing vaporiser (Diamedica Draw-over Vaporiser, Diamedica UK Ltd, Bratton Fleming, UK), to enable the delivery of 0.8% sevoflurane. Previous studies have suggested that self-administered sevoflurane at sub-anaesthetic concentration can provide useful pain relief during the first stage of labour and that it may be more effective than Entonox. Further research and potential clinical use have been impeded by the lack of a practical delivery system. In this study, the performance of two versions of the DSI (DSI-1 and DSI-2) was investigated. DSI-1 was tested over a range of minute volumes (1 to 30 l/min) and ambient temperatures (10°C to 40°C). The sevoflurane output increased unacceptably with rising ambient temperature, therefore the design was modified to create the DSI-2. The results from testing this revised version are also described. Mean sevoflurane output from the DSI-2 was found to be within a clinically acceptable range at the minute volumes tested (0.78% to 0.88%) and ambient temperatures tested (0.69% to 0.9%). Based upon these results, the authors propose to undertake further studies of sevoflurane analgesia using the DSI-2.
Sevoflurane is a non-irritant, volatile anaesthetic agent with a low blood gas partition coefficient of 0.65. This enables rapid uptake and fast washout from the central nervous system, resulting in swift onset and recovery. In 2007, Yeo et al determined the optimum concentration of sevoflurane needed to provide satisfactory analgesia with minimal sedation during labour to be 0.8% (equivalent to 0.44 times the minimum alveolar concentration [MAC] for surgical anaesthesia). There was a difference in analgesic effect of less than 5 mm on a visual analogue scale at inspired sevoflurane concentrations of 0.6% compared with 0.8%. Beyond 0.8%, there was no improvement in analgesia and excessive sedation did not occur until an inspired concentration of 1.2% was reached 1 .
Another study comparing self-administered sevoflurane with 50% nitrous oxide in oxygen (Entonox), in 29 healthy women in labour, demonstrated significantly better pain relief with sevoflurane. Most patients preferred sevoflurane to Entonox and found its sedative effects helpful, although two participants withdrew from the study because they preferred Entonox 2 . In addition, laboratory studies have suggested that sevoflurane reduces the infarct size in a model of neonatal asphyxia 3 and is associated with foetal brain protection in a perinatal rat model of hypoxia-ischaemia 4 . Other studies failed to demonstrate an analgesic effect at 0.35% (0.2 MAC) 5 .
Despite its possible advantages, sevoflurane labour analgesia has not been studied extensively, in part due to the absence of a suitable vaporiser. The Diamedica Sevoflurane Inhaler (Diamedica UK Ltd, Bratton Fleming, UK) (DSI) includes a draw-over vaporiser 6 which has been developed to administer 0.8% sevoflurane, to facilitate further investigation of its potential analgesic properties.
The design of the DSI
The DSI is supplied in a rigid, sealable, polypropylene copolymer container (Peli Products (UK) Ltd, Glossop, UK) measuring 30 cm × 25 cm × 20 cm, with a handle to make it easily transportable ( Figure 1) . The container holds a vaporiser, supplementary oxygen port, reservoir bag, air filter, a two-metre length of corrugated respiratory tubing and a unidirectional valve with mouthpiece. During use, the vaporiser is attached by a screw to the container to ensure stability and prevent accidental inversion. The total weight of the container and contents is 5 kg.
The manufacturer recommends that the vaporiser be empty during transportation and filled at the point of use. The agent-specific filling port is compatible with the filling devices used by the leading manufacturers of sevoflurane. By inverting the vaporiser after use, any residual agent can be returned to the bottle without spillage. If, against recommendation, the vaporiser is transported while containing residual agent, the construction of the device (without wicks) ensures that the liquid settles quickly, minimising excessive delivery of the agent to the patient. As with all vaporisers, incorrect use of the DSI-2, such as tilting or using the incorrect temperature setting, could result in the delivery of dangerous concentrations of sevoflurane.
The vaporiser ( Figure 2 ) is a modification of the standard Diamedica Draw-over Vaporizer (Diamedica UK Ltd, Bratton Fleming, UK) 7, 8 and is intended for self-administration of sevoflurane at a fixed concentration of 0.8%, using the accompanying breathing system. It features a 3.5 kg, 10 cm wide stainless steel vessel with inflow and outflow ports.
The splitting ratio is varied and controlled by moving the lever which controls the shuttle as it moves around the fixed obturator. The original vaporiser relied on thermal mass for temperature stability and a consistent output, together with alternative internal gas pathways, and these have all been retained in the DSI-1 and DSI-2.
A side window indicates the level of liquid sevoflurane in the chamber. The initial modification of the Diamedica Draw-over Vaporizer, the DSI-1 model, reduced the maximal vaporisation rate through two actions. The wicking material was removed from inside the vaporising chamber and the obturator position was changed to alter the flow dynamics within the device. The DSI-1 used in our initial experiments (phases 1 and 2) had a fixed splitting ratio with no dial to allow user adjustment of sevoflurane output and no ability to measure ambient temperature. The dial and temperature strip shown in Figure 3 were added following the initial experiments. The DSI-2 ( Figure 3 ) is a further modification, with the addition of an adjustable control lever which alters the splitting ratio according to ambient temperature, as displayed on an attached thermochromic strip thermometer (Good Life Innovations, Dorking, Surrey, UK). Although the control lever is continuously adjustable, it is intended to be locked by the user into a fixed position by a screw, which passes through one of four alternative holes in the top of the vaporiser into the threaded hole in the lever. Following the initial findings, the original fivehole settings were rationalised to four-hole settings.
The sevoflurane is normally delivered in air, but if oxygen supplementation is required, an oxygen port and reservoir bag is provided for attachment to the inflow port of the vaporiser (Figure 4 ).
The outflow port is connected to a two metre length of corrugated tubing, appropriate valve and either a mouthpiece or facemask. The single-use option comprises disposable tubing, a directional T-piece valve (Intersurgical code 1953) and a mouthpiece (Intersurgical code 1930). Alternatively, a reusable circuit consisting of silicone tubing, a Laerdal valve and a face mask can be provided ( Figure 5 ). The pressure drop across the assembled system is negligible (< 2 cmH 2 O). The aim of this study was to test the stability of sevoflurane output over a range of ventilatory patterns and ambient temperatures. Parameters were chosen to represent the physiological and environmental range expected in clinical situations or future research. Testing of the DSI-1, development of the temperature lever modification to create the DSI-2 and subsequent testing of this modification are described. Experiments were in vitro and ethical approval was therefore not required.
Methods
The study was completed in four phases. Throughout all phases a Diamedica Adult/Paediatric (Diamedica AP) ventilator was used and connected to the patient port of the Laerdal Valve. This ventilator incorporates a bellows which has a single, valveless connection to the 'Patient Circuit' port. The normal operation of this ventilator is to draw gases through the inlet at the back of the ventilator. For these experiments the inlet port was capped to allow the bellow to act as a simulated patient. Room air was used as the carrier gas in all experiments.
As the ventilator bellows inflated, the simulated inspiratory breath was drawn through the vaporiser and when the bellows deflated, the simulated expiration flowed out of the expiratory port of the Laerdal valve ( Figure 6 ).
Phase 1: Assessing the effect of varying respiratory patterns on DSI-1 sevoflurane output
The vaporiser temperature was maintained in room air at 20°C throughout this phase. The ventilator was set to deliver tidal volumes in 100 ml increments, between 100 ml and 1000 ml. At each tidal volume, the respiratory rate was adjusted to provide 10, 12, 15, 20 and 30 breaths per minute, giving a range of minute volumes between 1 and 30 l/ minute. The sevoflurane output concentration was measured continuously for a period of ten minutes at each ventilator setting, with values recorded to two decimal places, at twominute intervals, using a calibrated gas flow and volume sensor (QA-VTM ventilator tester; Fluke Biomedical, Everett, WA, USA and Mindray Beneview T8 Nan, Shenzhen Mindray Bio-medical Electronics Co. Ltd., Shenzhen, China).
Phase 2: Assessing the effect of varying ambient temperature on DSI-1 sevoflurane output
The Diamedica AP ventilator was set at a tidal volume of 400 ml and a frequency of 15 breaths per minute. The DSI-1 was placed in a Bennett Scientific Clifton thermostatic water bath (Bennett Scientific Ltd, Newton Abbot, Devon, UK), calibrated in line with the ISO13485 system. The water temperature was monitored continuously with both Mindray (Fluke Biomedical, as above) and Komodo (Komodo Combined Digital Thermometer and Hygrometer, Swell UK Ltd, Cheshire, UK) thermometers and was maintained at pre-selected values between 10°C and 40°C. The sevoflurane output (%) was measured every two seconds using the Mindray monitor. Readings commenced as soon as the water bath was stable at the desired temperature. On commencement of Phase 2 experiments, it became immediately apparent that ambient temperature adjustment was required. Diamedica, therefore, designed the DSI-2 with different lever settings to allow alteration of the splitting ratio according to ambient temperature.
Phase 3: Development of temperature adjustment modification (DSI-2)
The experimental equipment was set up as in Phase 2 and readings were taken at 5°C intervals, starting at 10°C. Once the water bath temperature had stabilised, a total of 30 readings were taken at two-second intervals. Our aim was to develop vaporiser settings which allowed sevoflurane delivery as close as possible to 0.8% and reliably within the 0.6% to 1.0% range. When the sevoflurane output deviated outside that range, the water bath was allowed to cool to determine the upper temperature limit providing an acceptable sevoflurane output for that lever setting. The next setting was used for temperatures beyond this and the process was repeated to establish the temperature range for each of the four settings, to a maximum water bath temperature of 40°C. The top of the vaporiser was then marked with settings to allow the lever position to be moved according to the displayed temperature. It was felt that sufficient accuracy could be obtained with four settings and these were marked with the following temperature ranges: 10°C to 17 o C, 18°C to 23 o C, 24°C to 33 o C and 34°C to 40 o C. Following these experiments, a thermochromic strip thermometer was attached externally to the vaporiser to display the ambient temperature.
Phase 4: Assessing the effect of varying the ambient air temperature on DSI-2 sevoflurane output
The four settings on the DSI-2 were tested for stability of sevoflurane output at varying ambient air temperatures likely to be encountered in clinical practice. Experiments were performed in an environmental chamber (Product Assessment and Reliability Centre Ltd, Bideford, UK), with thermostatically adjustable air temperature. The temperature of the DSI-2, as displayed on the thermochromic strip, was confirmed with a Picotech USB TC-08 thermocouple thermometer (Pico Technology, St Neots, Cambridgeshire, United Kingdom), set within the steel vessel via a small drilled hole. All temperatures were allowed to stabilise before readings commenced. The ventilator was set at a tidal volume of 400 ml and a frequency of 15 breaths per minute. The location of the environmental chamber precluded the use of the same Mindray gas analyser, so sevoflurane output was measured to a single decimal place using a portable Viamed VM-2500-MG multigas/SpO 2 monitor (Viamed Ltd, Keightly, West Yorkshire, UK) at three-second intervals for 60 readings. In order to ensure accuracy over the range of temperatures included at each lever position, the highest and lowest temperatures for each setting were tested (setting 1:10 and 17°C, setting 2:18 and 23°C, setting 3:24 and 33°C, setting 4:34 and 40°C).
Results

Phase 1
The mean sevoflurane output of the DSI-1 over the range of tidal volumes from 100 to 1000 ml and respiratory rates between 10 and 30 breaths per minute was 0.82% (range 0.78% to 0.88%) (Table 1, Figure 8 ). Higher sevoflurane outputs were associated with lower respiratory rates (10 breaths per minute; mean sevoflurane output range 0.82% to 0.88%) and vice versa (30 breaths per minute; mean sevoflurane output range 0.78% to 0.82%). Table 2 and Figure 9 show the results from the calibration of the DSI-2, completed in the water bath. During this experiment, the upper and lower ambient temperature limits for each ventilator setting were established, maintaining mean sevoflurane output within the range 0.72% to 0.89%. Only ten readings were possible at the 10°C setting, due to difficulty maintaining the water bath at this temperature.
Phase 3
Phase 4
The range of sevoflurane output at the temperature limits for each setting is shown in Table 3 . Setting 3 (24°C to 33°C) produced the widest range of output readings, with average readings 0.69% to 0.9%, whilst the other settings produced more consistent sevoflurane outputs. The minimum recorded sevoflurane output reading across all settings was 0.6% and maximum 0.9%, representing a variation in output of -25% to +12.5% around the desired 0.8%. Average readings at each temperature tested ranged from a minimum 0.69% to a maximum of 0.9%, representing a -14% to +12.5% variation around the optimum 0.8% sevoflurane output ( Figure 10 ).
Discussion
This study describes a process of design modification from the original prototype DSI-1 to the development of the DSI-2 and testing of this new version. The DSI-1 has been superseded by the DSI-2 as a result of these experiments. The use of vaporiser settings based on the measurement of ambient temperature is a unique feature of this design, assisting intuitive use, and we hope thereby improving safety. The method of thermo-compensation used has the benefit of minimising manufacturing costs and does not require electricity. It simply entails moving the lever to the position corresponding to the temperature reading on the thermochromic strip. In common with most medical equipment, it is imperative that full training is completed prior to the use of this device. However, the device is simple, small and mobile, implying that training might be short in duration and inexpensive to deliver. The DSI-2 allows patient-controlled administration without the need for expensive monitoring or excessive staff involvement and is currently commercially available.
The addition of an oxygen reservoir to the DSI enables the sevoflurane to be administered with a high concentration of oxygen, approaching 100% 9 . There is, therefore, a theoretical benefit to administration of sevoflurane from the DSI, in preference to Entonox, for pain relief when increased oxygen fractions are clinically required, such as foetal distress, shock, respiratory compromise or acute cardiac events.
Limited previous literature suggests that whilst 0.8% sevoflurane appears to be the optimal concentration for labour analgesia, a range of 0.6% to 1.0% appears to be safe and effective. The experiments described show that this range of output is achievable using the DSI over a range of ventilatory patterns and varying ambient temperatures. The maximum output recorded (0.9%) is below the unacceptable sedative level (1.2%) and the minimum output (0.6%) was observed for less than 15 seconds duration. Most importantly, none of the output readings recorded during our experiments deviated beyond the clinically appropriate range.
There are limitations to our study. Phase 2 experiments were abandoned before the investigation could be completed because a design change was required to provide a consistent output for the desired range of temperatures. It is our opinion that pursuing these experiments would not have added useful information. The output concentration depends on the correct positioning of the control lever. As with any vaporiser, if it is set incorrectly the output concentration will not reflect the concentration intended. It is therefore essential that the operator takes frequent temperature readings from the thermochromic strip and adjusts the position of the lever accordingly. The monitor used in the Phase 4 experiments only provided sevoflurane concentration to a single decimal place, but this is considered sufficiently accurate for clinical practice.
Analgesia options are advanced and varied in the developed world, with the ready availability of effective treatment, including oral medications, nerve blockade, patient-controlled opioid analgesia and nitrous oxide. This contrasts with the situation in less affluent areas where limits in logistics, personnel, equipment and finance result in limited analgesia services and much pain and suffering. For this reason, there is an urgent need for simple, effective, affordable and safe analgesic methods that can be delivered through community, pre-hospital and 
